Neurotrophic keratopathy: Clinical presentation and effects of cenegermin

PURPOSE: To report on 4 patients (3 adults, 1 child) with neurotrophic keratopathy (NK) treated with cenegermin 20 μg/ml (Oxervate®), a recombinant human nerve growth factor (rhNGF), which was authorized by the European Medicines Agency for the treatment of neurotrophic keratopathy stage 2 and stage...

Descripción completa

Detalles Bibliográficos
Autores principales: Bu, Julia Bing, Gericke, Adrian, Pfeiffer, Norbert, Wasielica-Poslednik, Joanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8938625/
https://www.ncbi.nlm.nih.gov/pubmed/35330588
http://dx.doi.org/10.1016/j.ajoc.2022.101488

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8938625/
https://www.ncbi.nlm.nih.gov/pubmed/35330588
http://dx.doi.org/10.1016/j.ajoc.2022.101488

Ejemplares similares